The MoatWide moat

Intuitive Surgical (ISRG) — moat facet

A toll collected per operation and enforced in firmware — which decides what share of a procedure Intuitive captures, and nothing at all about how many procedures happen.

Four things protect Intuitive, and the first one is not the machine.

The four numbers that describe the moat84%of 2025 revenuerecurring3,153,000da Vinci procedures1,810systems billingby usage5,600+issued patentsInstalled base 11,106 da Vinci systems at the end of 2025, up 12% on 1,721 placements.
A toll collected per operation, enforced in firmware, and backed by a patent estate. None of it sets how many operations happen.

The machine is a Class II medical device cleared under section 510(k) of the Federal Food, Drug, and Cosmetic Act — a route that requires a manufacturer to show its product is "substantially equivalent" to something already on the market1. It is the lowest regulatory bar in surgical devices, and the 10-K names fourteen companies that have introduced robotic products or stated an intent to2, including Johnson & Johnson and Medtronic. Whatever is holding this position, it is not a licence nobody else can get.

What holds it is the toll. Recurring revenue was 84% of the total in 20253, and the largest slice of it is consumables sold per procedure at a price the hospital does not renegotiate, on instruments that stop working after a prescribed number of uses because a chip inside them says so4. Intuitive gave away roughly nothing when it priced the system at about $1.6 million; the machine is the customer-acquisition cost.

The second is the surgeon. Robotic surgery is a motor skill learned on a specific console, and Intuitive has built an entire education apparatus around it — training pathways for surgeons, residents, operating-room teams and patient-side assistants, the SimNow simulator, the Intuitive Learning management system, proctoring and case observation5. About 3.15 million da Vinci procedures were performed in 2025. Every one of them deepened somebody's fluency in this system and nobody else's. A hospital that switched platforms would not be buying a machine; it would be retraining a department and accepting worse outcomes while it did.

The third is a change in the business model that is easy to miss. In 2025, 872 of 1,721 da Vinci placements — 51% — were operating leases rather than sales, and 496 of those were usage-based arrangements where Intuitive charges as procedures are performed6. The usage-based installed base has gone 1,023 to 1,492 to 1,810 in three years. Intuitive is converting itself from a capital-equipment vendor into a per-procedure toll collector, funded off a balance sheet with $8.63 billion of cash and no debt at all. The catch, which the company discloses, is that usage-based arrangements "generally contain no minimum payments; therefore, customers may exit such arrangements without paying a financial penalty"7.

The fourth is the patent estate and the accumulated engineering: more than 5,600 patents granted and in force and more than 2,500 pending8, twenty-seven years of clinical evidence, and a fifth-generation system with more than 10,000 times the computing power of its predecessor9. This facet is rated below the others because patents expire, because a 510(k) pathway is open to anyone who can show equivalence, and because the most credible rivals are two of the largest medical device companies on earth.

The honest limit on all four is that none of them touches demand. Intuitive's moat determines what share of a procedure's economics it captures. It does not determine how many procedures happen, and more than half of them are elective10. That distinction is what 2026 has been about.

The measure is return on invested capital: 17.0% in 2025 against an assumed 8% cost of capital11. That figure understates the operating business badly, because the standard denominator counts the $5.7 billion of short- and long-term investments Intuitive holds outside its cash line as working capital. Strip the whole $9.0 billion investment portfolio and the return on what actually operates is nearer 29%12. Either way the spread is real; the one to watch is whether it widens as the leasing book grows, because a leased system sits on Intuitive's balance sheet rather than the hospital's.

Moat trajectory: Holding steady

Recurring revenue is 84% of the total and the installed base grew 9,902 to 11,106. What has not improved is the rate at which the procedures underneath it grow, and in 2026 Intuitive volunteered to raise the permitted use count on select instruments — loosening the toll on purpose. A wide moat, holding its width, collecting a slightly thinner rate on a slightly slower-growing base.

The number that tests this moat
Moat Explorer calc
Return on invested capital vs an assumed 8% hurdle
17.0% in 2025, from 16.6% in 2016

Twice the hurdle, and understated: $8.6 billion of investments sits in the denominator doing no operating work, and the return on what actually operates is nearer 29%. If the moat is real the spread holds while the Extended Use Program lowers the toll; if not, this is where it shows first.

How it's calculated: NOPAT (operating income x (1 - effective tax rate)) divided by average operating invested capital (total assets less current liabilities less cash), computed from Intuitive's SEC XBRL filings by tools_roic_edgar.py. The 8% hurdle is an assumed WACC, not a filed figure.
The standard denominator leaves the whole $9.03 billion investment portfolio in invested capital. Excluding it raises the 2025 return to roughly 29%.
Source: Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 ↗
Aspects of the moat
DIG DEEPER 01
The Toll Is in the Instrument
The razor is $1.6 million and the blade expires on a counter Intuitive programmed itself.
DIG DEEPER 02
The Surgeon's Hands
The switching cost is a motor skill held by people Intuitive does not employ, and 3.15 million operations a year keep teaching it.
DIG DEEPER 03
From Selling Machines to Renting Them
Half the placements are now leases and 1,810 systems bill by the procedure: Intuitive is turning itself into a meter.
DIG DEEPER 04
Five Thousand Six Hundred Patents and a 510(k)
A very large patent estate protecting products cleared on the lowest regulatory pathway there is.
References
  1. ReportedThe machine is a Class II medical device cleared under section 510(k) of the Federal Food, Drug, and Cosmetic Act — a route that requires a manufacturer to show its product is "substantially equivalent" to something already on the market.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedIt is the lowest regulatory bar in surgical devices, and the 10-K names fourteen companies that have introduced robotic products or stated an intent to, including Johnson & Johnson and Medtronic.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedRecurring revenue was 84% of the total in 2025, and the largest slice of it is consumables sold per procedure at a price the hospital does not renegotiate, on instruments that stop working after a prescribed number of uses because a chip...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedRecurring revenue was 84% of the total in 2025, and the largest slice of it is consumables sold per procedure at a price the hospital does not renegotiate, on instruments that stop working after a prescribed number of uses because a chip...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedRobotic surgery is a motor skill learned on a specific console, and Intuitive has built an entire education apparatus around it — training pathways for surgeons, residents, operating-room teams and patient-side assistants, the SimNow...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  6. ReportedIn 2025, 872 of 1,721 da Vinci placements — 51% — were operating leases rather than sales, and 496 of those were usage-based arrangements where Intuitive charges as procedures are performed.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  7. ReportedThe catch, which the company discloses, is that usage-based arrangements "generally contain no minimum payments; therefore, customers may exit such arrangements without paying a financial penalty".
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  8. ReportedThe fourth is the patent estate and the accumulated engineering: more than 5,600 patents granted and in force and more than 2,500 pending, twenty-seven years of clinical evidence, and a fifth-generation system with more than 10,000 times...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  9. ReportedThe fourth is the patent estate and the accumulated engineering: more than 5,600 patents granted and in force and more than 2,500 pending, twenty-seven years of clinical evidence, and a fifth-generation system with more than 10,000 times...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  10. ReportedIt does not determine how many procedures happen, and more than half of them are elective.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  11. Moat Explorer calcThe measure is return on invested capital: 17.0% in 2025 against an assumed 8% cost of capital.
    Moat Explorer calculation from Intuitive's SEC XBRL filings (tools_roic_edgar.py): NOPAT divided by average operating invested capital, 17.0% in 2025 - and nearer 29% once the $9.03 billion investment portfolio, which does no operating work, is excluded from the denominator — 2015-2025 · publ. September 2026 · source ↗
  12. Moat Explorer calcStrip the whole $9.0 billion investment portfolio and the return on what actually operates is nearer 29%.
    Moat Explorer calculation from Intuitive's SEC XBRL filings (tools_roic_edgar.py): NOPAT divided by average operating invested capital, 17.0% in 2025 - and nearer 29% once the $9.03 billion investment portfolio, which does no operating work, is excluded from the denominator — 2015-2025 · publ. September 2026 · source ↗
Sources
Generated September 23, 2026